1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2026
European Organisation for Research and Treatment of Cancer - EORTCNot specified NCT03515993 Registry history of NCT03515993 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 1 | |
| Phase 2 | 12 | |
| Phase 2/3 | 1 | |
| Phase 3 | 14 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Retroperitoneal Sarcoma | Recruiting | 2026-10-07 |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | ER-positive Breast Cancer | Recruiting | 2026-10-07 |
| NCT06809322 | Vorasidenib Maintenance for IDH Mutant Astrocytoma | IDH-mutant Grade 2 or 3 Astrocytoma | Recruiting | 2026-10-07 |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma | Uveal Melanoma | Recruiting | 2026-06-30 |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a… | First Progression of Glioblastoma | Recruiting | 2026-06-08 |
| NCT05815927 | Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer | Oligometastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | 2026-05-28 |
| NCT05974774 | Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors | Prostate Cancer | Recruiting | 2025-09-19 |
| NCT02799706 | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH… | Prostate Cancer | Active, Not Recruiting | 2026-05-22 |
| NCT02194842 | Phase III Radium 223 mCRPC-PEACE III | Prostate Cancer | Active, Not Recruiting | 2025-09-19 |
| NCT00002462 | RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's… | Lymphoma | Active, Not Recruiting | 2025-08-05 |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With… | Lymphoma | Active, Not Recruiting | 2025-08-05 |
| NCT00379041 | Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With… | Lymphoma | Active, Not Recruiting | 2025-08-05 |
| NCT06407401 | Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy… | ER+ Breast Cancer | Not Yet Recruiting | 2024-11-05 |
| NCT00626990 | Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) | Brain and Central Nervous System Tumors | Active, Not Recruiting | 2023-09-11 |
| Phase 2/3 | ||||
| NCT07425808 | FLT3-ITD Targeted Therapy in Fit AML Patients | AML (Acute Myeloid Leukemia) | Not Yet Recruiting | 2026-02-23 |
| Phase 2 | ||||
| NCT06326190 | 177Lu-DOTATATE for Recurrent Meningioma | Recurrent Meningioma | Recruiting | 2026-06-15 |
| NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer | Metastatic Clear Cell Renal Cell Carcinoma | Recruiting | 2026-06-04 |
| NCT04128072 | Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB)… | Stage IB-IIB Cutaneous T-Cell Lymphoma | Recruiting | 2024-04-05 |
| NCT03517137 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single… | Advanced Hodgkin Lymphoma | Active, Not Recruiting | 2026-09-11 |
| NCT06219317 | Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC | NSCLC Stage IV | Active, Not Recruiting | 2026-06-23 |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy… | Non Small Cell Lung Cancer | Not Yet Recruiting | 2026-06-04 |
| NCT03134118 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | Thymoma Type B3 | Active, Not Recruiting | 2026-05-15 |
| NCT03609047 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer | Breast Cancer Stage II | Active, Not Recruiting | 2026-05-12 |
| NCT02972060 | ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer | Prostate Cancer | Active, Not Recruiting | 2025-09-19 |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With… | Unresectable Stage III Melanoma | Active, Not Recruiting | 2025-08-01 |
Breast Cancer (5) · Lung Cancer (5) · Prostate Cancer (5) · Glioma (4) · Hodgkin Lymphoma (4) · Melanoma (4) · Non-Small Cell Lung Cancer (NSCLC) (4) · Bladder Cancer (3) · Head & Neck Cancer (3) · Colorectal Cancer (2)